Thermo Fisher Scientific Inc. TMO SPXR3KPHARMA

Q: What is the current share price of Thermo Fisher Scientific Inc. (TMO)?

As of 2026-09-07 16:24 PDT, Thermo Fisher Scientific Inc. (TMO) trades at $608.52 on NYSE. Its 52-week range is $437.90 to $638.18.

Q: What is the market capitalisation of TMO?

Thermo Fisher Scientific Inc. (TMO) has a market capitalisation of $225.00B on NYSE.

Q: What is the P/E ratio of TMO?

TMO trades at a trailing price-to-earnings (P/E) ratio of 32.79. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.25.

Q: Does TMO pay a dividend?

Thermo Fisher Scientific Inc. (TMO) currently offers a dividend yield of 0.32%.

Q: What is the return on equity (ROE) of TMO?

TMO has a return on equity (ROE) of 13.51%. Its return on capital employed (ROCE) is 8.14%.

Q: Is TMO a good stock to buy?

This page provides a data-driven analysis of Thermo Fisher Scientific Inc. (TMO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Diagnostics & Research · United States

https://www.thermofisher.com

Company Profile ↓

$608.52

+25.98% 1Y

Mkt Cap$225.00B

P/E32.79

P/B4.25

Div. Yield0.32%

52W High$638.18

52W Low$437.90

Book Value$139.75

EPS (TTM)$18.56

Company Overview

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 13.0% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 15.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $44.56B (+3.9% YoY); net profit $6.70B.
Trailing 12 Months Year-on-year growth — revenue +10.5%, earnings +9.4%.
5-Year Trend Long-term compounding — revenue CAGR 8.8%, profit CAGR 13.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	8.81%
1 Year:	10.50%

Compounded Profit Growth

5 Years:	12.95%
1 Year:	9.40%

Stock Price Performance

1 Year:	+25.98%
6 Months:	+21.47%
3 Months:	+28.84%
1 Month:	+4.91%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 85% of range

$437.90 $638.18

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)54.62 · Neutral

Price Performance

1M+4.91%

3M+28.84%

6M+21.47%

1Y+25.98%

Valuation vs Sector

P/E of 32.79 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Profit CAGR of 13.0% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

32.79

Industry PE

25.17

Forward P/E

22.12

PEG Ratio

1.89

Book Value

$139.75

Price to Book

4.25

P/S

4.74

EV/EBITDA

22.00

Dividend Yield

0.32%

Growth (CAGR)

Revenue 5Y

8.81%

Profit 5Y

12.95%

Revenue (YoY)

10.50%

Earnings (YoY)

9.40%

Profitability & Returns

ROCE

8.14%

ROE

13.51%

ROA

5.13%

Profit Margin

15.04%

Op Margin

18.75%

Gross Margin

40.99%

EPS (Latest Qtr)

$4.68

EPS (TTM)

$18.56

Balance Sheet & Liquidity

Debt/Equity

0.81

Quick Ratio

1.01

Current Ratio

1.55

Debt

$42.55B

Total Assets

$113.17B

Current Assets

$23.36B

Working Capital

$8.30B

Ownership

Promoter Holding

0.13%

Chg in Prom Hold

-0.01%

FII / Inst Holding

94.14%

Chg in FII Hold

-0.27%

Financial Snapshot

Enterprise Value

$225.00B

Total Revenue (TTM)

$46.34B

EBITDA

$11.74B

Free Cash Flow

$6.24B

Operating Cash Flow

$9.01B

Shares Outstanding

369.75M

Gross Margin

40.99%

Payout Ratio

9.69%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	608.52	32.79	$225.00B	0.32%	8.14%	13.51%	8.81%	12.95%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Apr 2016	Jul 2016	Oct 2016	Dec 2016	Apr 2017	Jul 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Apr 2021	Jul 2021	Oct 2021	Apr 2022	Jul 2022	Oct 2022	Apr 2023	Jul 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	4.76B	4.99B	5.12B	6.05B	5.85B	6.08B	5.92B	6.51B	6.12B	6.32B	6.27B	6.83B	6.23B	6.92B	8.52B	9.91B	9.27B	9.33B	11.82B	10.97B	10.68B	10.71B	10.69B	10.57B	10.35B	10.54B	10.60B	10.36B	10.85B	11.12B	12.21B	11.01B	11.99B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.45B	6.54B	7.20B	6.58B	7.11B
Gross Profit	1.94B	1.88B	2.11B	1.96B	2.08B	2.05B	2.28B	2.19B	2.28B	2.30B	2.67B	2.58B	2.74B	2.62B	2.92B	2.71B	2.82B	2.76B	3.04B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.41B	4.58B	5.01B	4.43B	4.88B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.49B	2.51B	2.71B	2.52B	2.70B
Operating Income	595.80M	562.90M	-	517.90M	637.60M	541.10M	-	620.00M	749.00M	634.00M	-	786.00M	937.00M	912.00M	-	920.00M	1.50B	946.00M	-	906.00M	1.39B	2.43B	3.05B	2.16B	2.28B	2.82B	2.00B	1.71B	1.56B	1.58B	1.86B	1.66B	1.82B	1.84B	1.72B	1.92B	2.08B	2.30B	1.91B	2.19B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.80B	2.83B	3.25B	2.82B	3.14B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	404.00M	347.00M	365.00M	354.00M	401.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.71B	1.83B	2.15B	1.73B	1.92B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92.00M	207.00M	153.00M	70.00M	167.00M
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.55B	1.63B	1.51B	1.62B	1.62B	1.96B	1.65B	1.74B
Diluted EPS	1.27	1.18	1.50	1.01	1.30	1.19	1.59	1.40	1.56	1.34	1.30	1.43	1.85	1.75	2.22	2.02	2.77	1.88	2.49	1.97	2.90	4.84	5.88	4.61	4.79	5.61	4.22	3.79	3.32	3.51	4.42	3.46	4.04	4.25	3.98	4.28	4.27	5.21	4.43	4.68
R&D Expense	174.60M	171.60M	-	176.50M	182.40M	183.30M	-	215.00M	222.00M	217.00M	-	234.00M	242.00M	240.00M	-	248.00M	246.00M	247.00M	-	245.00M	264.00M	296.00M	320.00M	343.00M	351.00M	364.00M	365.00M	351.00M	346.00M	345.00M	319.00M	331.00M	339.00M	346.00M	342.00M	352.00M	346.00M	-	336.00M	364.00M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	9.75B	10.50B	9.91B	10.39B	11.56B	12.51B	13.09B	16.89B	16.96B	18.27B	20.92B	24.36B	25.54B	32.22B	39.21B	44.91B	42.86B	42.88B	44.56B
Operating Income	974.40M	1.23B	1.00B	1.19B	1.25B	1.48B	1.61B	2.50B	2.34B	2.46B	2.96B	3.78B	4.59B	7.79B	10.03B	8.39B	6.86B	7.34B	7.75B
Net Income	748.40M	980.90M	850.30M	1.04B	1.33B	1.18B	1.27B	1.89B	1.98B	2.02B	2.23B	2.94B	3.70B	6.38B	7.72B	6.95B	6.00B	6.33B	6.70B
Diluted EPS	1.69	2.25	2.01	2.53	3.46	3.21	3.48	4.71	4.92	5.09	5.59	7.24	9.17	15.96	19.46	17.63	15.45	16.53	17.74
R&D Expense	-	-	-	284.40M	340.20M	376.40M	395.50M	691.10M	692.00M	754.00M	887.00M	967.00M	1.00B	1.18B	1.41B	1.47B	1.34B	1.39B	1.40B

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	21.09B	21.62B	21.35B	26.83B	27.44B	31.86B	42.85B	40.83B	45.91B	56.67B	56.23B	58.38B	69.05B	95.12B	97.15B	98.73B	97.32B	110.34B
Total Equity	-	14.46B	14.93B	15.43B	15.36B	15.04B	15.46B	16.86B	20.55B	21.35B	21.54B	25.41B	27.59B	29.68B	34.51B	40.79B	43.98B	46.73B	49.58B	53.41B
Cash & Equivalents	667.40M	625.10M	1.28B	1.56B	917.10M	1.02B	805.60M	5.83B	1.34B	452.10M	786.00M	1.33B	2.10B	2.40B	10.32B	4.48B	8.52B	8.08B	4.01B	9.85B
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	17.72B	17.08B	19.11B	34.67B	34.28B	34.73B	31.07B	39.17B
Current Liabilities	-	-	1.54B	1.64B	1.71B	3.11B	2.09B	3.13B	5.35B	4.15B	4.87B	7.05B	6.15B	6.20B	10.30B	13.44B	17.01B	14.01B	13.33B	15.19B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	1.48B	1.42B	1.66B	1.50B	1.69B	2.04B	2.01B	2.62B	2.94B	3.26B	4.00B	4.54B	4.97B	8.29B	9.31B	9.15B	8.41B	8.67B	7.82B
Investing Cash Flow	-586.00M	-450.00M	-829.50M	-858.90M	-5.14B	-1.37B	-263.30M	-11.78B	-1.09B	-5.52B	-7.73B	-1.25B	-1.49B	-1.51B	-21.93B	-2.16B	-5.14B	-5.84B	-4.05B
Financing Cash Flow	-928.70M	-228.40M	-557.50M	-1.30B	-	-	-	-	-2.62B	2.76B	3.85B	-2.24B	-3.12B	959.00M	6.58B	-2.81B	-3.62B	-6.79B	1.80B
Capital Expenditure	-175.50M	-264.40M	-200.00M	-245.40M	-260.90M	-315.10M	-282.40M	-427.60M	-423.00M	-444.00M	-508.00M	-758.00M	-926.00M	-1.47B	-2.52B	-2.24B	-1.48B	-1.40B	-1.52B
Free Cash Flow	1.31B	1.16B	1.46B	1.25B	1.43B	1.72B	1.73B	2.19B	2.52B	2.81B	3.50B	3.79B	4.05B	6.82B	6.79B	6.91B	6.93B	7.27B	6.29B
Share Buybacks	898.00M	187.40M	414.60M	1.01B	1.34B	1.15B	89.80M	0	500.00M	1.25B	750.00M	500.00M	1.50B	1.50B	2.00B	3.00B	3.00B	4.00B	3.00B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	10.0%	11.7%	10.1%	11.4%	10.8%	11.8%	12.3%	14.8%	13.8%	13.5%	14.2%	15.5%	18.0%	24.2%	25.6%	18.7%	16.0%	17.1%	17.4%
Net Margin %	7.7%	9.3%	8.6%	10.0%	11.5%	9.4%	9.7%	11.2%	11.6%	11.1%	10.6%	12.1%	14.5%	19.8%	19.7%	15.5%	14.0%	14.8%	15.0%
ROE %	5.2%	6.6%	5.5%	6.7%	8.8%	7.6%	7.6%	9.2%	9.3%	9.4%	8.8%	10.7%	12.5%	18.5%	18.9%	15.8%	12.8%	12.8%	12.6%
ROCE %	-	6.3%	5.0%	6.0%	5.3%	5.8%	5.6%	6.7%	6.4%	6.0%	6.0%	7.6%	8.8%	13.3%	12.3%	10.5%	8.1%	8.7%	8.1%

Shareholding Pattern

Insiders

0.13%

Institutions

94.14%

Public Float

94.27%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.36%	30.92M	$19.24B
2	Vanguard Capital Management LLC	6.57%	24.28M	$15.10B
3	State Street Corporation	4.55%	16.83M	$10.47B
4	FMR, LLC	3.81%	14.08M	$8.76B
5	Morgan Stanley	2.91%	10.76M	$6.70B
6	JPMORGAN CHASE & CO	2.30%	8.50M	$5.29B
7	Geode Capital Management, LLC	2.27%	8.38M	$5.22B
8	Franklin Resources, Inc.	1.97%	7.27M	$4.52B
9	Vanguard Portfolio Management LLC	1.68%	6.23M	$3.87B
10	Capital World Investors	1.68%	6.20M	$3.85B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TMO

Google News Mon, 07 Sep 2026

Thermo Fisher Scientific (NYSE:TMO) Shows Strong Technical Breakout Setup - ChartMill

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPSkdMTVhEQ1lkUk52c25KWmRhZWhsUGVMRDFndmpGMzU4STB6MWJHeDJFbEY2MWVfdEIza1VfRWt6WEhFUHpLNm9kb3Q2QnR2Nk9DUFhkZ1g5ZThHX01xM3NqV3BZMF9aYXAxTzY5ODQtQUd2cGJJQmo1UUEtMFlBR1FHQkNwaDhoUVJ0Ml…

Google News Mon, 07 Sep 2026

Thermo Fisher Scientific Inc. (TMO) Stock Analysis: A Leading Healthcare Giant with Strong Revenue Growth Prospects - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxOTzhEbDZvNWlWdFA2WXF3U3hmVFJWZG1BUHd0ZjlPVDRlNkVzSE1MblpBMTFkSXEzX3NISzdIdV9fVVd0ZzhrbjdsUFhseXU3X0pPekJBQXRuTUVSMnhFTEZ3OHF0bzFvaXV0RHItcjhheENmSGJIVEMwb2VQS1VEd1ZXOENaazRRNmxqZj…

Google News Mon, 07 Sep 2026

Can Thermo Fisher Scientific (TMO) Justify Its Valuation After New Lab Product Launches? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOZmFpcDd5TjdHUEVZcDJZRlo5SDFYeHY4QjFmbUczT2VoN0VrTG9VeGF3OVdMYkM3TXM5NGRwbFBLRFFXczgxdXBQR0plZWtZOWJxa1YyYUprRm9jV0Y3T3M3VVFhTzBySklWNjBIUGRoeWpsa2pISFRYQWV0Q1BVNFA1WEF2bVc5NHotSD…

Google News Sat, 22 Aug 2026

Thermo Fisher (TMO) Stock Looks Fully Valued Following Its Microbiology Sale - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPVXFta25fYzllSmVnNkstemJMSktaSzNFbi1YQml6S3R4MzVpSnlTbjdjcFQ5ZV8zSS16WldXV3FlRVJHT2tXYnctLXUzMmpfODAyd2VNSWM4aXB5RmNjTFpRZUVXUkQ2V0tSZllXZ0dwQ3pOamFkaWNxVFNjeWFnQW9nWldxaThrNVhINn…

Google News Fri, 04 Sep 2026

Should You Continue to Hold TMO Stock in Your Portfolio? - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNZmlPa2JiWHhvZFBlUHdXM3UzaEd6alR2WWthU25rTUVRVmw2MW9COTlLSFdSS05RRVZweTRTUTR1THVKT0RpZU1XTFZJaGF1WTBxRExlbnBOd2VIY1JJWWZCVFRWeEZ2UnQ1dUR5VDBiZFk2QXY2VXpVMHo4UnozdXJ2dm9aZFhIanpBNG…

Google News hu, 20 Aug 2026

Why Thermo Fisher Scientific (TMO) Stock Is Up Today - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPZGhzbXlMb2NGM080b29hOHdGT09GQmdnWFZQNmtkc25KVHQ3MnUxZ2xGV1R0QnFZQTg1dzAtTDRaX01aR2lsS0Z2aGQ2bXRKWlJwZGlKaVc2SDZwbEtxMnhpcFVrSDB0ekR4YU1GWDhzWHZHN2wzT3JhY0t5Z0RHYzB4OHpCcDNoZW9vS3…

TMO — Frequently Asked Questions

What is the current share price of Thermo Fisher Scientific Inc. (TMO)?

As of 2026-09-07 16:24 PDT, Thermo Fisher Scientific Inc. (TMO) trades at $608.52 on NYSE. Its 52-week range is $437.90 to $638.18.

What is the market capitalisation of TMO?

Thermo Fisher Scientific Inc. (TMO) has a market capitalisation of $225.00B on NYSE.

What is the P/E ratio of TMO?

TMO trades at a trailing price-to-earnings (P/E) ratio of 32.79. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.25.

Does TMO pay a dividend?

Thermo Fisher Scientific Inc. (TMO) currently offers a dividend yield of 0.32%.

What is the return on equity (ROE) of TMO?

TMO has a return on equity (ROE) of 13.51%. Its return on capital employed (ROCE) is 8.14%.

Is TMO a good stock to buy?

This page provides a data-driven analysis of Thermo Fisher Scientific Inc. (TMO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Thermo Fisher Scientific Inc. TMO SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Thermo Fisher Scientific (NYSE:TMO) Shows Strong Technical Breakout Setup - ChartMill

Thermo Fisher Scientific Inc. (TMO) Stock Analysis: A Leading Healthcare Giant with Strong Revenue Growth Prospects - DirectorsTalk Interviews

Can Thermo Fisher Scientific (TMO) Justify Its Valuation After New Lab Product Launches? - simplywall.st

Thermo Fisher (TMO) Stock Looks Fully Valued Following Its Microbiology Sale - Yahoo Finance

Should You Continue to Hold TMO Stock in Your Portfolio? - Eastern Progress

Why Thermo Fisher Scientific (TMO) Stock Is Up Today - quiverquant.com

TMO — Frequently Asked Questions

What is the current share price of Thermo Fisher Scientific Inc. (TMO)?

What is the market capitalisation of TMO?

What is the P/E ratio of TMO?

Does TMO pay a dividend?

What is the return on equity (ROE) of TMO?

Is TMO a good stock to buy?

Explore More